{"acute myeloid leukaemia": 14.69, "adverse event": 2.61, "agranulocytosis": 3.56, "alopecia": 2.02, "anaemia": 2.65, "aphasia": 4.12, "aplastic anaemia": 51.92, "astrocytoma malignant": 700.5, "bone marrow failure": 29.6, "brain oedema": 11.13, "cholestasis": 4.99, "cytopenia": 4.65, "dermatitis": 4.43, "diabetes insipidus": 119.55, "disease progression": 14.24, "disease recurrence": 9.11, "drug eruption": 3.18, "drug ineffective": 2.66, "drug reaction with eosinophilia and systemic symptoms": 11.37, "drug resistance": 7.33, "drug-induced liver injury": 4.23, "eastern cooperative oncology group performance status worsened": 171.69, "febrile neutropenia": 5.35, "glioblastoma": 309.6, "glioblastoma multiforme": 271.53, "haematotoxicity": 50.25, "hemiparesis": 5.24, "hepatic failure": 2.72, "hepatotoxicity": 4.33, "hydrocephalus": 18.17, "hypermutation": 3504.95, "hypertransaminasaemia": 8.2, "infection": 2.33, "jaundice": 3.35, "leukopenia": 14.1, "liver injury": 5.41, "lymphopenia": 61.03, "malignant neoplasm progression": 5.89, "metastasis": 12.45, "mucosal inflammation": 3.87, "myelodysplastic syndrome": 21.49, "myelosuppression": 10.62, "neoplasm progression": 7.16, "neutropenia": 10.68, "pancytopenia": 26.35, "petechiae": 2.62, "platelet count decreased": 2.76, "platelet transfusion": 94.11, "pneumocystis jirovecii pneumonia": 14.13, "product substitution issue": 8.77, "product use in unapproved indication": 4.82, "rash maculo-papular": 3.09, "recurrent cancer": 29.98, "seizure": 2.6, "sepsis": 2.54, "skin reaction": 3.32, "therapeutic product effect incomplete": 3.52, "thrombocytopenia": 33.32, "toxicity to various agents": 7.8, "treatment failure": 4.04, "tumour pseudoprogression": 362.36, "white blood cell count decreased": 2.03}